THERAPEUTIC POTENTIAL OF HPMPC AS AN ANTIVIRAL DRUG

[21] EFFECTIVE CHEMOTHERAPY OF EQUINE HERPESVIRUS-1 BY PHOSPHONYLMETHOXYALKYL DERIVATIVES OF ADENINE DEMONSTRATED IN A NOVEL MURINE MODEL FOR THE DISEASE [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (05) : 709 - 717

[22] ISOLATION OF EQUINE HERPESVIRUS-1 MUTANTS IN THE PRESENCE OF (S)-9-(3-HYDROXY-2-PHOSPHONYLMETHOXYPROPYL)ADENINE - DEMONSTRATION OF RESISTANCE INVITRO AND INVIVO [J]. ANTIVIRAL RESEARCH, 1991, 16 (01) : 29 - 39

[23] FLORESAGUILAR M, 1993, UNPUB LONG ACTING TR

[24] THE ACTIVITY OF (S)-1-[(3-HYDROXY-2-PHOSPHONYL METHOXY) PROPYL] CYTOSINE (HPMPC) AGAINST EQUINE HERPESVIRUS-1 (EHV-1) IN CELL-CULTURES, MICE AND HORSES [J]. ANTIVIRAL RESEARCH, 1992, 19 (03) : 219 - 232

[25] COMPARATIVE EFFICACY OF BROAD-SPECTRUM ANTIVIRAL AGENTS AS INHIBITORS OF AFRICAN SWINE FEVER VIRUS-REPLICATION INVITRO [J]. ANTIVIRAL RESEARCH, 1987, 7 (03) : 151 - 160

[26] PHOSPHONYLMETHOXYALKYLPURINES AND PHOSPHONYLMETHOXYALKYLPYRIMIDINES AS INHIBITORS OF AFRICAN SWINE FEVER VIRUS-REPLICATION INVITRO [J]. ANTIVIRAL RESEARCH, 1987, 8 (5-6) : 273 - 281

[27] THE EFFECT OF (S)-1-(3-HYDROXY-2-PHOSPHONYL-METHOXYPROPYL)CYTOSINE (HPMPC) ON BOVINE HERPESVIRUS-1 (BHV-1) INFECTION AND REACTIVATION IN CATTLE [J]. ANTIVIRAL RESEARCH, 1993, 20 (01) : 21 - 32

[28] EARLY TREATMENT WITH GANCICLOVIR TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (23) : 1601 - 1607

[29] LONG-TERM INTRAVITREAL GANCICLOVIR THERAPY FOR CYTOMEGALO-VIRUS RETINOPATHY [J]. ARCHIVES OF OPHTHALMOLOGY, 1989, 107 (12) : 1767 - 1772

[30] HO HT, 1992, MOL PHARMACOL, V41, P197

[21] EFFECTIVE CHEMOTHERAPY OF EQUINE HERPESVIRUS-1 BY PHOSPHONYLMETHOXYALKYL DERIVATIVES OF ADENINE DEMONSTRATED IN A NOVEL MURINE MODEL FOR THE DISEASE [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (05) : 709 - 717

[22] ISOLATION OF EQUINE HERPESVIRUS-1 MUTANTS IN THE PRESENCE OF (S)-9-(3-HYDROXY-2-PHOSPHONYLMETHOXYPROPYL)ADENINE - DEMONSTRATION OF RESISTANCE INVITRO AND INVIVO [J]. ANTIVIRAL RESEARCH, 1991, 16 (01) : 29 - 39

[23] FLORESAGUILAR M, 1993, UNPUB LONG ACTING TR

[24] THE ACTIVITY OF (S)-1-[(3-HYDROXY-2-PHOSPHONYL METHOXY) PROPYL] CYTOSINE (HPMPC) AGAINST EQUINE HERPESVIRUS-1 (EHV-1) IN CELL-CULTURES, MICE AND HORSES [J]. ANTIVIRAL RESEARCH, 1992, 19 (03) : 219 - 232

[25] COMPARATIVE EFFICACY OF BROAD-SPECTRUM ANTIVIRAL AGENTS AS INHIBITORS OF AFRICAN SWINE FEVER VIRUS-REPLICATION INVITRO [J]. ANTIVIRAL RESEARCH, 1987, 7 (03) : 151 - 160

[26] PHOSPHONYLMETHOXYALKYLPURINES AND PHOSPHONYLMETHOXYALKYLPYRIMIDINES AS INHIBITORS OF AFRICAN SWINE FEVER VIRUS-REPLICATION INVITRO [J]. ANTIVIRAL RESEARCH, 1987, 8 (5-6) : 273 - 281

[27] THE EFFECT OF (S)-1-(3-HYDROXY-2-PHOSPHONYL-METHOXYPROPYL)CYTOSINE (HPMPC) ON BOVINE HERPESVIRUS-1 (BHV-1) INFECTION AND REACTIVATION IN CATTLE [J]. ANTIVIRAL RESEARCH, 1993, 20 (01) : 21 - 32

[28] EARLY TREATMENT WITH GANCICLOVIR TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (23) : 1601 - 1607

[29] LONG-TERM INTRAVITREAL GANCICLOVIR THERAPY FOR CYTOMEGALO-VIRUS RETINOPATHY [J]. ARCHIVES OF OPHTHALMOLOGY, 1989, 107 (12) : 1767 - 1772

[30] HO HT, 1992, MOL PHARMACOL, V41, P197